FDA Approves New Treatment for Essential Thrombocythemia
The FDA approved ropeginterferon alfa-2b, marketed as BESREMi, for the treatment of adults diagnosed with essential thrombocythemia. This development marks the first new therapeutic option for this rare blood cancer in nearly 30 years. Essential thrombocythemia occurs when the bone marrow produces excessive platelets, which significantly elevates the risk for dangerous blood clots and internal bleeding. PharmaEssentia, the manufacturer, confirmed the regulatory milestone in a statement released on September 1, 2026.
Ropeginterferon is designed as a long-acting, interferon-based therapy to provide stable disease control. The approval covers patients regardless of their specific disease genotype. It is also available for newly diagnosed adults who have not previously undergone cytoreductive therapy. This drug previously gained regulatory approval for the treatment of polycythemia vera, providing clinicians with a familiar pharmacological profile for managing myeloproliferative neoplasms.
Results from the SURPASS ET Trial
Clinical evidence supporting this approval originated from the open-label SURPASS ET trial. Researchers enrolled 174 adults with essential thrombocythemia who showed either an inadequate response or a specific intolerance to hydroxyurea. Participants were split into two groups, with 91 receiving ropeginterferon and 83 receiving anagrelide. Both groups maintained a standard regimen of low-dose aspirin unless a specific contraindication existed.
The findings were statistically significant. Data collected between months nine and twelve showed that 37.4% of patients receiving ropeginterferon achieved a positive response. In contrast, only 3.6% of those in the anagrelide group met the same criteria. The study defined success using modified European LeukemiaNet standards. This metric included blood count remission, nonprogression of splenomegaly, and the absence of any new bleeding or thrombotic events.
Safety Profile and Clinical Administration
Every medication carries risks, and ropeginterferon is no exception. The most frequent adverse reactions reported during clinical monitoring included transaminase elevations and anemia. Patients also experienced fever, bacterial infections, pruritus, and weight loss. The official product labeling contains a black box warning alerting healthcare providers to potential neuropsychiatric, autoimmune, ischemic, and infectious complications.
Physicians start treatment at a dosage of 250 µg administered via subcutaneous injection. The protocol requires an increase to 350 µg after two weeks. By the fourth week, the patient reaches a maintenance dosage of 500 µg. Clinicians administer this maintenance dose every two weeks, though they must adjust the timing or amount if the patient struggles with tolerability. Proper monitoring of liver enzymes and blood counts remains a critical component of the care plan for those on this therapy. As the medical community integrates this drug into standard practice, the primary focus will remain on balancing thrombotic risk reduction against these documented adverse effects.